• AbbVie’s Teliso-V Granted BTD in NSCLC contractpharma
    January 04, 2022
    For the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC).
PharmaSources Customer Service